JPMorgan raised the firm’s price target on Travere Therapeutics to $23 from $20 and keeps an Overweight rating on the shares. The analyst updated models in the Smid-cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
- Travere Therapeutics price target raised to $23 from $18 at Canaccord
- Travere upgraded to Buy at Guggenheim after IgAN approval, ahead of FSGS updates
- Travere Therapeutics upgraded to Buy from Neutral at Guggenheim
Questions or Comments about the article? Write to editor@tipranks.com